A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)

Phase 2CompletedNCT01285752

Asahi Kasei Therapeutics Corporation240 enrolled

Overview

To investigate the efficacy and safety of AK106-001616 in patients with rheumatoid arthritis.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

240

Conditions

Rheumatoid Arthritis

Interventions

AK106-001616DRUG

Active comparatorDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of RA (class I to III) * Stable dose of methotrexate (at least 12 weeks) Exclusion Criteria: * Pregnant or breastfeeding * Abnormal screening laboratory test values considered to be clinically significant

Locations (26)

Unnamed facility

Hlučín, Czechia

Unnamed facility

Hostivice, Czechia

Unnamed facility

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.